^
    4years
    Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. (PubMed, Clin Lung Cancer)
    No intra- or intertumor heterogeneity was observed for EGFR compound mutations. Our results indicate that both EGFR mutations were truncal and selective elimination of cancer cells with uncommon EGFR mutations is unrealistic.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR L858R • EGFR G719X • EGFR S768I • EGFR G719A • EGFR G719X + EGFR S768I • EGFR E709G • EGFR G719A + EGFR S768I • EGFR L858R + EGFR R776H • EGFR L858R + EGFR S768I
    4years
    Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. (PubMed, Oncologist)
    Afatinib treatment at 40 mg daily is associated with high rates of adverse events and dose reductions; alternative strategies including pulse intermittent dosing should be evaluated prospectively. Osimertinib (with favorable safety profile and intracranial penetration) has shown promising results in this population in a phase II trial from South Korea; additional trials are ongoing.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR L858R + EGFR T790M • EGFR G719X • EGFR S768I • EGFR G719A • EGFR G719X + EGFR S768I • EGFR L861Q + EGFR G719X • EGFR L858R + EGFR exon 19 deletion • EGFR T790M + KRAS mutation • EGFR mutation + EGFR T790M • EGFR G719A + EGFR S768I • EGFR L858R + EGFR S768I • EGFR exon 19 deletion + EGFR S768I • EGFR T790M + exon 19 deletion
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    over4years
    [VIRTUAL] Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) patients from East Asia. (ASCO 2020)
    "Uncommon, potentially actionable EGFR mutations were found in 9% of plasma samples from East Asian NSCLC patients. In this clinical practice dataset, uncommon EGFR mutations were more prevalent than actionable biomarkers in other genes. These data support the use of NGS testing methods to identify NSCLC patients for appropriate EGFR-targeted therapy."
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • RET fusion • MET exon 14 mutation • EGFR L861Q • MET mutation • EGFR S768I • EGFR positive • EGFR G719A • EGFR L718Q • EGFR L858R + EGFR exon 19 deletion • EGFR G719A + EGFR S768I • EGFR L858R + EGFR S768I • EGFR exon 19 deletion + EGFR S768I
    |
    Guardant360® CDx